Scarica l'app Stockscreener
1.165
0.43%
-0.005
Dopo l'orario di chiusura:
1.15
-0.015
-1.29%
Opus Genetics Inc Borsa (IRD) Ultime notizie
Ocuphire Pharma Acquires Opus Genetics - Marketscreener.com
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - StreetInsider.com
North Carolina gains public company with merger - The Business Journals
Ocuphire buys Opus Genetics, grows gene therapy pipeline - The Pharma Letter
Ocuphire Pharma Announces Acquisition of Opus Genetics - Vision Monday
Ocuphire Shares Rise After Extended US Patent For Nyxol Eye Drops Secured - Marketscreener.com
Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics - Yahoo Finance
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal - AOL
Ocuphire and Opus Genetics merge to develop IRD gene therapy - Yahoo Finance
Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders - Business Wire
AAO 2024: Epimacular membranes and metamorphopsia - Ophthalmology Times
Ocuphire Pharma acquires Opus Genetics in all-stock deal By Investing.com - Investing.com Australia
Wilson Sonsini Advises Opus Genetics on IP Matters Related to Acquisition by Ocuphire Pharma - Wilson Sonsini
Ocuphire Pharma acquires Opus Genetics in all-stock deal - Investing.com
Ocuphire Pharma acquires Opus Genetics - Seeking Alpha
News in Cell and Gene Therapy for Rare Cancer Day 2024 - CGTLive™
EyeCon 2024: Taking a multidisciplinary approach to diabetic eye care - Optometry Times
EURETINA 2024: Aleksandra Rachitskaya, MD, FASRS, and the Vit-Buckle Society come to Barcelona - Ophthalmology Times Europe
VEW 2024: Touring the retina with Dr. Steven Ferrucci - Optometry Times
Barry J Byrne, MD, PhD, on Making Decisions in the Face of Rapidly Expanding Treatment Options - CGTLive™
Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy - Ophthalmology Times
Ocuphire Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
William Chou, MD, on Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations - CGTLive™
PHOTON Results and Their Relation to DME Patients in Your Practice - Ophthalmology Times Europe
ASRS 2024: A novel approach to myopic traction maculopathy - Ophthalmology Times Europe
ASRS 2024: Diabetic retinopathy lesions and assessing disease severity over time - Ophthalmology Times Europe
Vertex’s Diabetes Cell Therapy on Track to Meet Endpoint of Eliminating Severe Hypoglycemic Events - CGTLive™
Gene Therapy Improves Body Composition in Mice Models of Obesity Alone and After Semaglutide Withdrawal - CGTLive™
Salvador Rico, MD, PhD, on Developing Gene Regulation Therapy for Dravet Syndrome - CGTLive™
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration - CGTLive™
Around the Helix: Cell and Gene Therapy Company Updates – June 19, 2024 - CGTLive™
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility - CGTLive™
Around the Helix: Cell and Gene Therapy Company Updates – June 12, 2024 - CGTLive™
Department of HealthAbu Dhabi and Opus Genetics Announce Collaboration to Advance Ground-Breaking Gene Therapy Research for Inherited Retinal Diseases - PR Newswire
Intellia’s Phase 3 Clinical Trial for CRISPR-Based Gene Therapy Enrolls First Patient - CGTLive™
Amit Soni, MD, on Treating the First Patient With Hemophilia A Gene Therapy in the Real-World Setting - CGTLive™
Verve Moves on to Second Gen Cardiovascular CRISPR Therapy After Adverse Events - CGTLive™
Vision loss's role in accessibility advocacy with Rebecca Alexander - Optometry Times
Nanoscope Therapeutics lead candidate MCO-010 meets endpoints in RESTORE trial for retinitis pigmentosa - Modern Retina
John A. Charlson, MD, on Afami-Cel’s Upcoming Review for Synovial Sarcoma - CGTLive™
Frederick “Eric” Arnold, PhD, on Investigating Alternative Polyadenylation in ALS Models - CGTLive™
Alexis Kuhn, PharmD, BCOP, on Hemoglobinopathy Gene Therapies From a Pharmacist’s Perspective - CGTLive™
symbol__ Stock Quote Price and Forecast - CNN
EyePod: Modifier Gene Therapy: What is it? - Ophthalmology Times
David Shyr, MD, on Surprising Findings With CRISPR Cell Therapy Nula-Cel in Sickle Cell Disease - CGTLive™
Passage Bio’s Gene Therapy PBFT02 Positively Impacts Biomarker Levels in Patients With Frontotemporal Dementia - CGTLive™
Kadimastem and iTolerance Work to Bring Immunosuppression-Free Diabetes Cell Therapy to Trials - CGTLive™
Vertex Pauses Diabetes Cell Therapy Trial After Unrelated Patient Deaths - CGTLive™
New tools emerge for the early detection of hydroxychloroquine maculopathy - Optometry Times
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials - Ophthalmology Times Europe
Roger Hajjar, MD, on Gene Therapy as a Novel Precision Medicine Modality in Cardiology - CGTLive™
Krystal Biotech's Side Business: Gene-Based Aesthetics - Life Science Leader Magazine
Islet Cell Pouch Implantation Shows Promise in Type 1 Diabetes - CGTLive™
Artificial intelligence in eye care - Optometry Times
Dry age-related macular degeneration: The second city of AMD - Optometry Times
Paul Hahn, MD, PhD, shares insights on pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy - Optometry Times
ASRS 2023: Fernando Arevalo on retinal detachments associated to retinoschisis - Ophthalmology Times Europe
Case report: Refractory pseudophakic cystoid macular edema during an exacerbation of scleroderma - Optometry Times
DR:EAM study: Exploring eye drops for diabetic retinopathy - Optometry Times
Jennifer Morganroth, MD, MBA, on the Importance of Preparing Clinical Resources for Genetic Medicines - CGTLive™
Geographic atrophy, pegcetacoplan, and the future of care with Dr. Euin Cheong - Optometry Times
No Time to Pause: Companies Abandon Lagging Cell Therapy Programs - CGTLive™
Heart Failure iPSC-Derived Therapy Trial Doses First Patient - CGTLive™
Study: Nanotechnology may improve gene therapy for blindness - Ophthalmology Times
Opus Genetics acquires two gene therapy candidates from Iveric Bio - Healio
Clinical Hold Lifted on Homology’s pheNIX Trial for Phenylketonuria - CGTLive™
Carsten Bönnemann, MD, on Identifying At-Risk Genotypes for DMD Gene Therapy - CGTLive™
Portal extension trial: PDS maintains visual and anatomic benefits over long term - Ophthalmology Times Europe
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):